Curated News
By: NewsRamp Editorial Staff
February 10, 2026
Stonegate Initiates Coverage on AB Science, Highlighting Masitinib's Neurological Promise
TLDR
- Stonegate Capital Partners' coverage initiation on AB Science highlights masitinib's potential as a first-in-class therapy for ALS, progressive MS, and AD, offering investors early access to a promising biotech portfolio.
- AB Science's masitinib is an oral tyrosine kinase inhibitor targeting mast-cell and microglia pathways, with Phase 3 trials authorized in the US and EU for progressive MS, supported by grant financing.
- Masitinib's development for ALS, progressive MS, and Alzheimer's disease represents hope for millions of patients facing neurodegenerative conditions with limited treatment options.
- AB Science's masitinib uniquely targets neuroinflammation through mast cells and microglia, offering a novel approach to treating multiple neurodegenerative diseases simultaneously.
Impact - Why it Matters
This news matters because it spotlights a potential breakthrough in treating debilitating neurological diseases like ALS, progressive MS, and Alzheimer's, which currently have limited effective therapies. For patients and families affected by these conditions, the advancement of masitinib could represent a new hope for slowing disease progression and improving quality of life. From an investment and healthcare innovation perspective, the coverage by a firm like Stonegate validates AB Science's research approach and could accelerate funding and partnerships, potentially bringing this treatment to market faster. The broader impact lies in addressing the growing global burden of neurodegenerative diseases, which strain healthcare systems and devastate lives, making any clinical progress in this field critically important.
Summary
Stonegate Capital Partners, a prominent capital markets advisory firm, has initiated coverage on AB Science S.A., a late-stage biotechnology company. This move signals increased institutional attention on AB Science's promising pipeline, which centers on masitinib, an oral tyrosine kinase inhibitor designed to target maladaptive neuroinflammation. The company is positioning this drug as a potential add-on therapy for several challenging neurological conditions, including Amyotrophic Lateral Sclerosis (ALS), progressive forms of Multiple Sclerosis (MS), and Alzheimer's Disease (AD).
The coverage highlights key clinical progress, noting that the ALS program is supported by prior Phase 2b/3 data, while the Phase 3 trial for progressive MS is authorized in the United States and twelve European Union countries, with approximately 94 sites initiating. Additionally, the company's financing is bolstered by grants, providing a stable foundation for its research. Beyond masitinib, AB Science maintains earlier-stage potential with its asset AB8939 in Acute Myeloid Leukemia (AML), offering investors optionality within its portfolio. The announcement emphasizes the combination of a treatment for ALS and the broader portfolio's potential as exciting developments to monitor.
For those seeking more details, the full announcement, including downloadable images and bios, is available; interested parties can click here to access the comprehensive report. The news was distributed by Reportable, Inc., and originates from Stonegate, Inc., underscoring the formal and reportable nature of this financial initiation. This coverage initiation by Stonegate Capital Partners represents a significant vote of confidence in AB Science's strategic direction and its potential to address unmet medical needs in neurology and oncology.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Stonegate Initiates Coverage on AB Science, Highlighting Masitinib's Neurological Promise
